双强领跑1月15日,港股上市企业巨子生物发布自愿性公告,宣布其全资子公司陕西巨子生物技术有限公司收到国家药品监督管理局颁发的关于重组I型α1亚型胶原蛋白及透明质酸钠复合溶液产品的《中华人民共和国医疗器械注册证》(注册证编号:国械注准20263130044)。巨子生物公告称,该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品,通过器审与药审联合审评正式获批。从主要成分来...
Source Link双强领跑1月15日,港股上市企业巨子生物发布自愿性公告,宣布其全资子公司陕西巨子生物技术有限公司收到国家药品监督管理局颁发的关于重组I型α1亚型胶原蛋白及透明质酸钠复合溶液产品的《中华人民共和国医疗器械注册证》(注册证编号:国械注准20263130044)。巨子生物公告称,该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品,通过器审与药审联合审评正式获批。从主要成分来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.